Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder
|
Luke Timmerman |
11/20/09 |
Boston
|
|
Dendreon FDA Deadline Set For May 1
|
Luke Timmerman |
11/20/09 |
Seattle
|
|
Metcalfe Reflects on $2.7B 3Com Buyout, MyPunchbowl Parent Adds New Punch, $30M More for Fate Therapeutics, & More Boston Deals News
|
Ryan McBride |
11/20/09 |
Boston
|
|
Under the Radar Deals: 12 Northwest Financings You Haven’t Heard About
|
Gregory T. Huang |
11/20/09 |
Seattle
|
|
Omeros Banks on First FDA Filing Next Year, Plans to “Unlock” Inaccessible Drug Targets
|
Luke Timmerman |
11/19/09 |
Seattle
|
|
ImmunoGen Nabs $1M From Amgen
|
Luke Timmerman |
11/19/09 |
Boston
|
|
Big Energy Collaborations Seen to Jump-Start Emerging Biofuels Technologies
|
Bruce V. Bigelow |
11/19/09 |
San Diego
|
|
Ligand Nabs $2M From Merck
|
Luke Timmerman |
11/19/09 |
San Diego
|
|
Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore
|
Luke Timmerman |
11/19/09 |
Boston
|
|
Isis Extends Timeline on Cholesterol-Lowering Drug, FDA Delays Review of Cadence Pain Reliever, Fate Therapeutics Raises $30 Million, & More San Diego Life Sciences News
|
Denise Gellene |
11/19/09 |
San Diego
|
|
The Icos Alumni Guide, Trubion CEO Resigns, OVP Leads $30M Fate Deal, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/19/09 |
Seattle
|
|
Beyond Anecdotes: Measuring Global Health Impact in Washington State
|
Lisa Cohen |
11/18/09 |
Seattle
|
|
Genzyme Halts Development of New Kidney Drug; A “Very Significant” Bust, Analyst Says
|
Luke Timmerman |
11/18/09 |
Boston
|
|
Biotech Meets Cleantech: GenVault Aims to Deep Six the Laboratory Deep Freeze
|
Denise Gellene |
11/18/09 |
San Diego
|
|
NanoString Forges Closer Ties With Broad Institute to See What Genetic Tool Can Really Do
|
Luke Timmerman |
11/18/09 |
Seattle
|
|
The Icos Alumni: Where Are They Now?
|
Luke Timmerman |
11/18/09 |
Seattle
|
|
Isis, Genzyme Cholesterol Drug Passes Test, But Investors Get Nervous About Liver Safety
|
Luke Timmerman |
11/17/09 |
San Diego
|
|
Bing Partners with Wolfram Alpha, OVP Leads $30M Fate Deal, Redfin Rakes In $10M, & More Seattle-Area Deals News
|
Gregory T. Huang |
11/17/09 |
Seattle
|
|
Trubion CEO Peter Thompson Steps Down, Arch’s Gillis To Step Up Temporarily
|
Luke Timmerman |
11/16/09 |
Seattle
|
|
Fate Therapeutics Bags $30M Venture Deal, Led by OVP, to Develop “Industrialized” Stem Cells
|
Luke Timmerman |
11/16/09 |
National
|
|
Cadence Hit By FDA Delay
|
Luke Timmerman |
11/13/09 |
San Diego
|
|
Genzyme Shares Tank After FDA Discovers Bits of Steel, Rubber in Five Different Drugs
|
Luke Timmerman |
11/13/09 |
Boston
|
|
Xconomy Videos: Sirtris’ Westphal and Millennium’s Dunsire Talk Cures for Ills of Big Pharma
|
Ryan McBride |
11/13/09 |
Boston
|
|
Cyntellect Raises $15.5M as it Expands Biotech Instrument Business
|
Bruce V. Bigelow |
11/12/09 |
San Diego
|
|
Cequent Seeks First Oral RNAi Trial
|
Luke Timmerman |
11/12/09 |
Boston
|
|
Oncothyreon Advances Cancer Drug
|
Luke Timmerman |
11/12/09 |
Seattle
|
|
Massachusetts Startup Funding Slowed Way Down in October—But Early Stage Deals Gained
|
Robert Buderi |
11/12/09 |
Boston
|
|
Trius Therapeutics Reveals Plans for IPO, SpectraScience Raises $4.3M, Sequenom Tightens its Belt, & More San Diego Life Sciences News
|
Denise Gellene |
11/12/09 |
San Diego
|
|
Alder’s Breakout $1B Deal, Kineta Teams With UW on Vaccines, Verathon Gets Acquired, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/12/09 |
Seattle
|
|
Isis Spinoff Altair Therapeutics Closes $17M Venture Round For Asthma Drug
|
Luke Timmerman |
11/12/09 |
San Diego
|
|
Page 1 of
70 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
